Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Zusen Wang"'
Publikováno v:
Journal of Pancreatology, Vol 7, Iss 1, Pp 90-95 (2024)
The incidence rate of pancreatic tuberculosis (PT) is low, and it is difficult to distinguish from pancreatic malignant tumor before operation. We present 3 patients diagnosed after surgical treatment. All 3 cases involved female patients who were ad
Externí odkaz:
https://doaj.org/article/c1eeb54bc0004866aa2423ba1165caf2
Autor:
Zusen Wang, Yongxing Li, Shixiong Zhan, Lu Zhang, Shun Zhang, Qian Tang, Miaomiao Li, Zhen Tan, Shiguo Liu, Xiaoming Xing
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Abnormal SMAD4 expression also plays an important role in the malignant progression of PDAC. Methods We investigated
Externí odkaz:
https://doaj.org/article/f6569232e00141388a2ba94bdfa37899
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Background: Long noncoding ribonucleic acid (lncRNA) X-inactive-specific transcript (Xist) was reported to affect cell proliferation and metastasis in hepatocellular carcinoma (HCC). However, there are rare reports focusing on the diagnostic evaluati
Externí odkaz:
https://doaj.org/article/061a4b5ec2f244d7bb3bcb5be704a3ef
Autor:
Zhenhui Lu, Chang Liu, Feng Xia, Rongshou Zheng, Ying-Jian Liang, Yijun Yang, Wenling Wang, Rui Mao, Zhiwen Luo, Suxia Luo, Shida Yan, Minshan Chen, Jianqiang Cai, Xiaoying Wang, Zhiyu Li, Qinggang Hu, Jian Zhou, Dong Yan, Jing Tan, Yi Ba, Jianjun Zhao, Xuewen Zhang, Xun Li, Yujun Xie, Xiaofeng Zhu, Bo Chen, Bixiang Zhang, Qichen Chen, Feng Zhang, Aimin Yue, Dianrong Xiu, Xu Che, Hong Zhao, Muxing Li, Yajin Chen, Liming Wang, Jianguo Zhou, Yubao Zhang, Feng Shen, Yamin Zhang, Yue Han, Qingdong Li, Aiping Zhou, Duo Li, Yanqiao Zhang, Tao Peng, Mingyan He, Xuejun Zhang, Xiaowei Dang, Xueli Bai, Xinyu Bi, Caifeng Gong, Wenqiang Wei, Tingbo Liang, Ning Li, Zusen Wang, Yilei Mao, Zhen Huang, Tianqiang Song, Ping Yue, Xiao Chen, Rui Zhang, Lianxin Liu, Changzhen Shang, Yuan Tang, Yong Zeng, Xiujun Cai, Po Yang, Yefan Zhang, Bin Liu, Yongkun Sun, Jing Jin
Publikováno v:
HPB : The Official Journal of the International Hepato Pancreato Biliary Association
Background This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic. Methods A nationwide online questionnaire survey
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ba2b10994b3943cdaa5b2ce4928ac55
http://europepmc.org/articles/PMC8312214
http://europepmc.org/articles/PMC8312214
Publikováno v:
BioMed Research International, Vol 2019 (2019)
BioMed Research International
BioMed Research International
Aim. Little is known about the association between cancer antigen 125 (MUC16/CA125) concentrations and tumor diameter of patients with hepatocellular carcinoma (HCC) and low AFP levels. To fill this gap in our knowledge, we conducted a retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4929ac2ed082cea18a40f6f36d0b203
https://doi.org/10.1155/2019/6959637
https://doi.org/10.1155/2019/6959637
Publikováno v:
European Journal of Surgical Oncology. 45:1684-1690
Background Management of recurrent hepatocellular cancer (HCC) after liver resection is challenging, with unsatisfactory long-term patient outcomes. Liver re-resection, in theory, is a good treatment option. We therefore studied prognosis and risk fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db2e048274ca169cef754a7452d04ba4
https://doi.org/10.1016/j.ejso.2019.04.008
https://doi.org/10.1016/j.ejso.2019.04.008
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 9 (2017)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background: Long noncoding ribonucleic acid (lncRNA) X-inactive-specific transcript (Xist) was reported to affect cell proliferation and metastasis in hepatocellular carcinoma (HCC). However, there are rare reports focusing on the diagnostic evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b12ebd0202a7f7ff1e591f877b3613d5
https://doi.org/10.1177/1758834017731052
https://doi.org/10.1177/1758834017731052
Publikováno v:
Oncotarget
YY1 is a DNA-binding transcription factor and reported to be involved in cancer progression. Histone deacetylase inhibitor (HDACi) could inhibit proliferation and promote apoptosis of Hepatocellular carcinoma (HCC) cells. However, it is unclear about
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aba5067d253844af002e9418c67479e
https://doi.org/10.18632/oncotarget.17196
https://doi.org/10.18632/oncotarget.17196
Publikováno v:
Translational Cancer Research. 6:247-253
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0baf997db99f0b05ca5b573590881a10
https://doi.org/10.21037/tcr.2016.11.78
https://doi.org/10.21037/tcr.2016.11.78
Autor:
Miaomiao Li, Shun Zhang, Lu Zhang, Shiguo Liu, Yongxing Li, Qian Tang, Shixiong Zhan, Zhen Tan, Xiaoming Xing, Zusen Wang
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Background SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Abnormal SMAD4 expression also plays an important role in the malignant progression of PDAC. Methods We investigated SMAD4 sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4f60461d7111a039778d3fe695a3ddd
https://pubmed.ncbi.nlm.nih.gov/31684910
https://pubmed.ncbi.nlm.nih.gov/31684910